Literature DB >> 2750834

Conjunctival deposition of eosinophil granule major basic protein in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis.

S D Trocme1, G M Kephart, M R Allansmith, W M Bourne, G J Gleich.   

Abstract

To investigate the role of the eosinophil in vernal keratoconjunctivitis and contact lens-associated giant papillary conjunctivitis, we assessed the presence of eosinophil granule major basic protein in conjunctival tissues by immunofluorescence. Biopsy specimens of conjunctiva were taken from nine patients with vernal keratoconjunctivitis, seven patients with giant papillary conjunctivitis, and five control subjects. We performed a masked semiquantitative assessment of immunofluorescence on sections from each specimen. The vernal keratoconjunctivitis and giant papillary conjunctivitis groups had significantly (P less than .05) more major basic protein deposition than controls. No significant correlation between severity of disease and degree of major basic protein deposition was found. We found extracellular eosinophil granules in one of three vernal keratoconjunctivitis specimens examined by transmission electron microscopy. Thus, eosinophil degranulation commonly occurs in vernal keratoconjunctivitis and giant papillary conjunctivitis with release of eosinophil granule major basic protein and presumably other toxic granule proteins onto affected tissues. These cationic proteins are potent cytotoxins and are able to stimulate mast cell degranulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2750834     DOI: 10.1016/s0002-9394(14)73261-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

Review 1.  Ocular mast cells. Characterization in normal and disease states.

Authors:  E B Cook; J L Stahl; N P Barney; F M Graziano
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  Allergic ocular disease. A review of pathophysiology and clinical presentations.

Authors:  L Bielory; P E Goodman; E M Fisher
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

3.  Chemokines in the limbal form of vernal keratoconjunctivitis.

Authors:  A M Abu El-Asrar; S Struyf; S A Al-Kharashi; L Missotten; J Van Damme; K Geboes
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 4.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

5.  Eosinophil granule proteins expressed in ocular cicatricial pemphigoid.

Authors:  A Heiligenhaus; J Schaller; S Mauss; S Engelbrecht; J E Dutt; C S Foster; K P Steuhl
Journal:  Br J Ophthalmol       Date:  1998-03       Impact factor: 4.638

6.  Efficacy of nedocromil 2% versus fluorometholone 0.1%: a randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis.

Authors:  K F Tabbara; S A al-Kharashi
Journal:  Br J Ophthalmol       Date:  1999-02       Impact factor: 4.638

7.  Eosinophil cationic protein in tears in allergic conjunctivitis.

Authors:  P G Montan; M van Hage-Hamsten
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

8.  Impairment of ocular surface epithelium barrier function in patients with atopic dermatitis.

Authors:  K Yokoi; N Yokoi; S Kinoshita
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

9.  Clinical and biological efficacy of preservative-free NAAGA eye-drops versus levocabastine eye-drops in vernal keratoconjunctivitis patients.

Authors:  A Leonardi; D Bremond-Gignac; M Bortolotti; D Violato; P Pouliquen; L Delval; J M Grouin; I A Fregona
Journal:  Br J Ophthalmol       Date:  2007-06-21       Impact factor: 4.638

10.  M cells are involved in pathogenesis of human contact lens-associated giant papillary conjunctivitis.

Authors:  Xingwu Zhong; Hongshan Liu; Aijun Pu; Xuefeng Xia; Xiaodong Zhou
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007-06-08       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.